Valbiotis Launches Operations in Asia

Valbiotis, a French laboratory, has announced the launch of its operations in Asia through a joint venture with the Chinese group Aika. The venture, which is 49% owned by Valbiotis, is now fully operational alongside its Hong Kong subsidiary. Initial orders have been confirmed for commercialization in China and Hong Kong in late 2026. The strategic move aligns with a prior agreement signed in November 2025.

The joint venture, named Hangzhou Valbiotis Life Health Technology Co. Ltd., will commercialize ValbiotisPRO® products. It includes a €3M cash contribution from Aika and a planned additional €2M in funding. Marketing efforts will leverage major Chinese e-commerce platforms like Tmall Global and JD Worldwide.

Valbiotis is also exploring additional Asian markets, targeting Vietnam, Indonesia, Japan, and Taiwan. Concurrently, they're initiating traditional registration processes in China for future distribution. The company offers a 20% shareholder discount on specific products.